ALCHEMIST Screening Trial

Full Title

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST Screening Trial)

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Sponsor: National Cancer Institute

Investigator(s)

Division(s)

Research Type

Contact Information

Juile Ward, RN, BSN

412-647-8583

wardj@upmc.edu

Eligibility

For pre-surgical patients

 ◦Suspected diagnosis of resectable non-small cell lung cancer

◦Suspected clinical stage of IIIA, II or large IB (defined as size >= 4cm)

For post-surgical patients

 ◦Completely resected non-small cell lung cancer

◦Pathologic stage IIIA, II or IB (defined as size >= 4 cm)

For all patients

•No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer

•No prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas; a secondary primary lung cancer is considered a concurrent malignancy and would make a patient ineligible.

•No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4

For more information, https://clinicaltrials.gov/ct2/show/NCT02194738